Source: NETAG
Area: Evidence > Drug Specific Reviews
The NHS North East Treatment Advisory Group (NETAG) was requested to re-appraise bevacizumab (Avastin®) for the treatment of diabetic macular oedema in light of NICE not having recommended ranibizumab (Lucentis®) for the same indication. The group considered the evidence of the previous appraisal which included bevacizumab for DMO (October 2010) and was disappointed that the additional clinical evidence was of a similar low methodological quality. In addition, it noted substantial variations in the evaluated treatment and monitoring regimens and a general paucity of longer-term data. It acknowledged that intravitreal bevacizumab represents use of the drug outside of its product license and duly considered the pertinent issues which this presents.
Overall, the group could not recommend bevacizumab for diabetic macular oedema as it was concerned about the quality of clinical evidence supporting bevacizumab in DMO and in particular evidence relating to the durability of ...
Uncategorized